In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Additional drug shows promise for women with triple-negative breast cancer
NCI Cancer Center News
(Posted: 12/16/2013) - In a nationwide study of women with triple-negative breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of patients whose tumors shrank away completely, investigators reported at the 2013 San Antonio Breast Cancer Symposium. The study, sponsored by the Cancer and Leukemia Group B, includes authors from the Dana-Farber Cancer Institute, Brown University, the University of Texas MD Anderson Cancer Center, the UNC Lineberger Comprehensive Cancer Center. New York University, Washington University in St. Louis, City of Hope Comprehensive Cancer Center, and Mount Sinai Medical Center.

Lung cancer death rates continue to fall, helping drive decrease in overall cancer death rates; Annual Report to the Nation includes special feature highlighting the contribution of other diseases on survival of patients
NCI Press Release
(Posted: 12/16/2013) - The Annual Report to the Nation on the Status of Cancer, covering the period 1975–2010, showed death rates for lung cancer, which accounts for more than one in four cancer deaths, dropping at a faster pace than in previous years. The recent larger drop in lung cancer deaths is likely the result of decreased cigarette smoking prevalence over many years, and is now being reflected in mortality trends
View the article in Spanish

New models of drug-resistant breast cancer point to better treatments
NCI Cancer Center News
(Posted: 12/13/2013) - Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research from Washington University School of Medicine (home of the Alvin J. Siteman Cancer Center) in St. Louis, presented Dec. 12 at the San Antonio Breast Cancer Symposium.

Ibrutinib and rituximab trigger 95 percent response rate among CLL patients
NCI Cancer Center News
(Posted: 12/13/2013) - Nearly all of the high-risk chronic lymphocytic leukemia patients in a phase II clinical trial responded to treatment with the targeted therapy ibrutinib and the antibody rituximab, researchers from The University of Texas MD Anderson Cancer Center reported at the 55th Annual Meeting of the American Society of Hematology.

New presurgery combination therapy may improve outcomes for women with triple-negative breast cancer
NCI Cancer Center News
(Posted: 12/13/2013) - The I-SPY 2 trial, an innovative, multidrug, phase II breast cancer trial, has yielded positive results with the first drug to complete testing in the trial. Adding the chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved outcomes for women with triple-negative breast cancer, according to results from the I-SPY 2 trial (led by researchers from the UCSF Helen Diller Family Comprehensive Cancer Center) presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Changing chemo not beneficial for metastatic B.C. patients with elevated circulating tumor cells
NCI Cancer Center News
(Posted: 12/13/2013) - For women with metastatic breast cancer who had elevated amounts of circulating tumor cells (CTCs) in their blood after a first line of chemotherapy, switching immediately to a different chemotherapy did not improve overall survival or time to progression, according to the results of a phase III clinical trial presented by researchers from the University of Michigan Comprehensive Cancer Center at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Study identifies highly effective treatment option for patients with HER2-positive breast cancer
NCI Cancer Center News
(Posted: 12/12/2013) - Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study (led by researchers from the UCLA Jonsson Comprehensive Cancer Center) presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

Combined therapy linked to lower chance of recurrence in women with small, HER2-positive breast cancers
NCI Cancer Center News
(Posted: 12/12/2013) - In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers report at the 2013 San Antonio Breast Cancer Symposium.

Multi-gene test could help spot breast cancer patients most at risk
NCI Cancer Center News
(Posted: 12/12/2013) - A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test, whose development was led by researchers from the University of Chicago (home of the University of Chicago Comprehensive Cancer Center) and described in the Dec. 11 issue of PLOS ONE, was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and Oncotype, as well as to extend its predictions to patients with more advanced or difficult-to-treat cancers.

Gene sequencing project finds family of drugs with promise for treating childhood tumor
NCI Cancer Center News
(Posted: 12/11/2013) - Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle and other soft tissue. The findings are the latest from the St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project and appear in the December 9 edition of the scientific journal Cancer Cell.

< Previous  4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24  Next >